Ishita Drugs & Industries Ltd Board to Consider Q2 FY27 Results

Ishita Drugs & Industries Ltd will consider unaudited Q2 FY27 results for the quarter ended September 30, 2026, at its board meeting on November 3, 2026. The meeting follows Q1 FY27 revenue of ₹3.15 crore, which was down 41.8% year on year, while net profit stood at ₹0.23 crore.

What will Ishita Drugs consider at its November 3 board meeting?

Ishita Drugs will consider and approve its unaudited financial results for Q2 FY27 at the scheduled board meeting on Tuesday, November 3, 2026. The results will cover the three months ended September 30, 2026, which is the July-September quarter of the company’s financial year.

The advance intimation was made under Regulation 29 of the Securities and Exchange Board of India’s Listing Obligations and Disclosure Requirements Regulations, 2015. This provision requires listed companies to inform stock exchanges in advance about board meetings where financial results are proposed to be considered.

The November meeting relates to Q2 FY27, rather than the June-ended first quarter. Ishita Drugs had earlier scheduled a board meeting on August 8, 2026, to consider unaudited results for the quarter ended June 30, 2026. Those Q1 FY27 results are the latest reported financial reference available before the September-quarter announcement.

How did Ishita Drugs perform in Q1 FY27?

Ishita Drugs reported Q1 FY27 revenue of ₹3.15 crore and net profit of ₹0.23 crore for the quarter ended June 30, 2026. Revenue was 41.8% lower than the corresponding quarter a year earlier, while net profit declined 23.3% year on year, based on the reported quarterly figures.

On a sequential basis, the June-quarter revenue was reported at ₹3.18 crore by another quarterly data summary, compared with ₹3.27 crore in the March 2026 quarter. That comparison indicated a 2.75% quarter-on-quarter decline in revenue. The figures are reported at slightly different rounding levels across the available disclosures and summaries.

Quarterly EBITDA for June 2026 was reported at ₹0.35 crore, compared with ₹0.31 crore in March 2026, a 12.9% sequential increase. Net profit of ₹0.23 crore also compared with ₹0.18 crore in the preceding March quarter, representing a 27.78% sequential increase. The company’s reported Q1 FY27 operating margin was 10.1%.

Why is the trading window closed before the Q2 FY27 announcement?

Ishita Drugs closed its trading window for designated persons from October 1, 2026, ahead of the Q2 FY27 results process. The restriction will continue until 48 hours after the company declares the unaudited financial results for the quarter ended September 30, 2026.

Trading-window closures are a standard compliance measure intended to prevent trading by persons who may have access to unpublished price-sensitive information. The company’s disclosure identifies the September-quarter results as the event linked to the restriction and specifies the reopening condition rather than a fixed reopening date.

The timing also aligns with the company’s earlier communication on results-related governance. Investors will be able to assess Q2 performance only after the board considers the accounts and the results are disclosed to the exchanges.

What does the Q1 performance mean ahead of the Q2 results?

The reported Q1 FY27 figures show that Ishita Drugs entered the September quarter after a sharp year-on-year decline in revenue, alongside a smaller decline in net profit. The difference between the revenue and profit movements suggests that profitability was relatively more resilient than sales during the June quarter, although both metrics remained below their respective year-earlier levels.

A separate earnings summary reported a 7.2% profit margin for the June quarter, compared with 5.6% in the year-earlier quarter, and attributed the improvement to lower expenses. This should be read alongside the reported operating-margin figure of 10.1%, as the two measures are not the same and may use different bases of calculation.

For investors, the Q2 disclosure will provide the next confirmed data point on revenue, profitability and cost trends. No share-price movement, earnings guidance or business outlook linked to the forthcoming results was provided in the available information, so the market impact cannot be quantified before the formal announcement.

What recent corporate actions has Ishita Drugs completed?

Ishita Drugs held its 33rd annual general meeting on September 30, 2026. Shareholders adopted the FY26 financial statements, approved related-party transactions and sanctioned the appointment of statutory auditors for FY27.

The resolution concerning adoption of the audited FY26 financial statements received 99.99% votes in favour. The meeting also approved the re-appointment of M/s Jaymin Shah & Associates as statutory auditors for the 2026-27 period.

These actions provide the governance backdrop to the Q2 FY27 results meeting. The board’s November 3 decision will be focused on the unaudited September-quarter financial statements, while the annual accounts for FY26 have already been placed before and adopted by shareholders.

Conclusion

Ishita Drugs is scheduled to consider Q2 FY27 unaudited results on November 3, following a June quarter in which revenue was ₹3.15 crore and net profit was ₹0.23 crore. The available figures show weaker year-on-year revenue and profit, but sequential improvement in EBITDA and net profit compared with the March 2026 quarter.

Investors will watch the formal Q2 FY27 disclosure for confirmed revenue, profit and margin figures for the quarter ended September 30, 2026. The trading window will reopen 48 hours after the results declaration, as stated by the company.